Center for Innovation and Creativity
Boulder, Colorado, 80301, United States
NCT Number: NCT05868213
This study investigates the impact of ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on recognition memory in healthy, regular cannabis users. Participants complete the same recognition memory task after self-administering one of three different strains of cannabis flower one day and while not intoxicated another day. Event-related potentials (ERPs) are measured via electroencephalogram (EEG) during the recognition memory task. Blood is collected to quantify THC and CBD exposure. Participants also complete self-report measures of medical history, sleep quality, subjective cognitive function, physical activity, psychological functioning, substance use, and acute drug effects.
Looking for future studies?
Notify Me21 year–40 year
All sexes
Observational
Boulder, Colorado, 80301, United States
Previous research has established cannabis's harmful cognitive impact, with particularly robust and consistent effects in the domain of verbal episodic memory. However, prior work has not sufficiently considered that the memory effects of cannabis are the compound action of different cannabinoids, which vary in their pharmacology and effects. Specifically, CBD, a non-psychotomimetic component of cannabis (doesn't produce a "high"), is thought to have cognitively protective properties and may mitigate some of the harmful effects of THC. Further, few prior studies have tested the effects of high potency strains that are commonly available.
This study tests the effects of commercially available cannabis flower strains on recognition memory performance and ERPs that are related to different underlying memory processes in healthy, regular cannabis users. An episodic memory task is used to assess recognition memory, which asks participants to discriminate between previously studied and non-studied items using words as stimuli. Participants complete the same memory task while intoxicated one day and not intoxicated another day. A THC-dominant, a CBD-dominant, and a strain containing both THC and CBD are included in the study. Participants self-administer one of the three cannabis strains prior to memory encoding and retrieval.
Blood is collected to determine THC and CBD exposure, as well as to explore how genetic variation in genes related to cannabinoid metabolism, cannabis-related behavior, and neurocognitive function associate with memory function before and after cannabis use. Participants also complete self-report measures of medical history, sleep quality, subjective cognitive function, physical activity, psychological functioning, substance use, and acute drug effects.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Self-Directed Use (ad-libitum)
Time frame: intoxicated session and not-intoxicated session
Electroencephalography is used to quantify FN400 and parietal ERP effects.
Time frame: intoxicated session and not-intoxicated session (about 1 week)
Accuracy and reaction time will be used to assess task performance.
Time frame: intoxicated session and not-intoxicated session (about 1 week)
Accuracy and reaction time will be used to assess task performance.
Time frame: intoxicated session and not-intoxicated session (about 1 week)
Electroencephalography is used to quantify ERN effects.
Time frame: before and after acute cannabis use (about 30 minutes)
The PANAS is Self-report measurement of positive and negative affect.
Time frame: before and after acute cannabis use (about 30 minutes)
The DEQ is a visual analogue scale of measure of acute drug effects.
Time frame: before and after acute cannabis use (about 30 minutes)
The ARCI-M is a self-report measure of subjective effects of marijuana.
Time frame: before and after acute cannabis use (about 30 minutes)
The Marijuana Craving Questionnaire is a self-report measure of marijuana craving.
Time frame: before and after acute cannabis use (about 30 minutes)
The POMS is a self-report measure of mood.
Time frame: before and after acute cannabis use (about 30 minutes)
The Alcohol Craving Questionnaire is a self-report measure of alcohol craving.
Time frame: before and after acute cannabis use (about 30 minutes)
The SAPC-B is a self-report measure of paranoia.
Time frame: baseline, intoxicated session, and not-intoxicated session (about 3 weeks)
Blood levels of THC and CBD will be quantified.
Time frame: baseline, intoxicated session, and not-intoxicated session (about 3 weeks)
DNA samples are collected from a baseline blood sample.
Time frame: baseline, intoxicated session, and not-intoxicated session (about 3 weeks)
Baseline health and psychological function include measures of sleep quality, affective symptoms, and substance use history.
University of Colorado, Boulder
Other
ERP Studies of Acute Influences of THC and CBD on Memory Encoding and Retrieval Processes: Experiment 1
Acronym: COBRA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06669585
Cannabis, Chemically-Induced Disorders
Boulder, Colorado, United States
View Trial DetailsNCT07679581
Cannabis, Chemically-Induced Disorders
Boulder, Colorado, United States
View Trial DetailsNCT05351905
Cannabis, Chemically-Induced Disorders
Toronto, Ontario, Canada
View Trial DetailsNCT06218550
Cannabis, Chemically-Induced Disorders
Baltimore, Maryland, United States
View Trial Details